After valve-in-valve transcatheter aortic valve implantation (TAVI), dual antiplatelet therapy (DAPT) may reduce the risk of stroke compared to single antiplatelet therapy (SAPT).
No significant differences were observed between DAPT and SAPT regarding major adverse cardiac and cerebrovascular events, major bleeding, or mortality within one year.
Structural valve deterioration rates were low and similar between treatment strategies at one-year follow-up.
